On Monday, contract drugmaker Catalent Inc. (CTLT.N) said it expected to “significantly” lower its 2023 sales and core profit expectations and delay its third-quarter results by a week.
Company shares dropped 20% before the bell.
In April, Catalent warned that poor output and higher-than-expected expenditures at three locations, including two major manufacturing plants, would hurt fiscal 2023 profits.
On Monday, the business claimed it had found major forecasting errors over the last year and was fixing them.
Last week, Catalent uncovered potential non-cash adjustments linked to its Bloomington, Indiana facilities, requiring additional examination of its third-quarter results.
It stated that these challenges would require it to cut its fiscal 2023 net sales and adjusted EBITDA expectations by more than $400 million each.
The corporation plans to file its quarterly report on May 15, not Tuesday.
Comment Template